Literature DB >> 18619669

Progress in matrix metalloproteinase research.

Gillian Murphy1, Hideaki Nagase.   

Abstract

Matrix metalloproteinases (MMPs) are now acknowledged as key players in the regulation of both cell-cell and cell-extracellular matrix interactions. They are involved in modifying matrix structure, growth factor availability and the function of cell surface signalling systems, with consequent effects on cellular differentiation, proliferation and apoptosis. They play central roles in morphogenesis, wound healing, tissue repair and remodelling in response to injury and in the progression of diseases such as arthritis, cancer and cardiovascular disease. Because of their wide spectrum of activities and expression sites, the elucidation of their potential as drug targets in disease or as important features of the repair process will be dependent upon careful analysis of their role in different cellular locations and at different disease stages. Novel approaches to the specific regulation of individual MMPs in different contexts are also being developed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18619669      PMCID: PMC2810947          DOI: 10.1016/j.mam.2008.05.002

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  198 in total

1.  Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA.

Authors:  T J Smeets; M C Kraan; S Galjaard; P P Youssef; M D Smith; P P Tak
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

2.  Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome.

Authors:  J A Martignetti; A A Aqeel; W A Sewairi; C E Boumah; M Kambouris; S A Mayouf; K V Sheth; W A Eid; O Dowling; J Harris; M J Glucksman; S Bahabri; B F Meyer; R J Desnick
Journal:  Nat Genet       Date:  2001-07       Impact factor: 38.330

3.  Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain.

Authors:  M L Patterson; S J Atkinson; V Knäuper; G Murphy
Journal:  FEBS Lett       Date:  2001-08-17       Impact factor: 4.124

4.  Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis.

Authors:  M P Herman; G K Sukhova; W Kisiel; D Foster; M R Kehry; P Libby; U Schönbeck
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

5.  Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells.

Authors:  Natalia D Marchenko; George N Marchenko; Robert N Weinreb; James D Lindsey; Ainura Kyshtoobayeva; Howard C Crawford; Alex Y Strongin
Journal:  Int J Biochem Cell Biol       Date:  2004-05       Impact factor: 5.085

6.  Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition.

Authors:  Meng-Huee Lee; Magdalini Rapti; Vera Knaüper; Gillian Murphy
Journal:  J Biol Chem       Date:  2004-01-20       Impact factor: 5.157

7.  Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction.

Authors:  Shunji Hayashidani; Hiroyuki Tsutsui; Masaki Ikeuchi; Tetsuya Shiomi; Hidenori Matsusaka; Toru Kubota; Kyoko Imanaka-Yoshida; Takeshi Itoh; Akira Takeshita
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-05-29       Impact factor: 4.733

8.  Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase.

Authors:  Yi I Wu; Hidayatullah G Munshi; Ratna Sen; Scott J Snipas; Guy S Salvesen; Rafael Fridman; M Sharon Stack
Journal:  J Biol Chem       Date:  2003-12-11       Impact factor: 5.157

9.  Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression.

Authors:  Simon Hughes; Olorunsola Agbaje; Rebecca L Bowen; Deborah L Holliday; Jacqueline A Shaw; Stephen Duffy; J Louise Jones
Journal:  Clin Cancer Res       Date:  2007-11-15       Impact factor: 12.531

10.  Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption.

Authors:  Peng Hou; Tine Troen; Maria C Ovejero; Tove Kirkegaard; Thomas L Andersen; Inger Byrjalsen; Mercedes Ferreras; Takuya Sato; Steven D Shapiro; Niels T Foged; Jean-Marie Delaissé
Journal:  Bone       Date:  2004-01       Impact factor: 4.398

View more
  203 in total

1.  Metalloproteinase processing of HBEGF is a proximal event in the response of human aortic endothelial cells to oxidized phospholipids.

Authors:  Sangderk Lee; James R Springstead; Brian W Parks; Casey E Romanoski; Roland Palvolgyi; Tiffany Ho; Phuc Nguyen; Aldons J Lusis; Judith A Berliner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03-08       Impact factor: 8.311

Review 2.  The role of targeted chemical proteomics in pharmacology.

Authors:  Chris W Sutton
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Fell-Muir Lecture: Metalloproteinases: from demolition squad to master regulators.

Authors:  Gillian Murphy
Journal:  Int J Exp Pathol       Date:  2010-08       Impact factor: 1.925

4.  Variability in melanoma metalloproteinase expression profiling.

Authors:  Orsi Giricz; Janelle L Lauer; Gregg B Fields
Journal:  J Biomol Tech       Date:  2010-12

5.  Embryonic exposure to tetrabromobisphenol A and its metabolites, bisphenol A and tetrabromobisphenol A dimethyl ether disrupts normal zebrafish (Danio rerio) development and matrix metalloproteinase expression.

Authors:  Jessica M McCormick; Michael S Paiva; Max M Häggblom; Keith R Cooper; Lori A White
Journal:  Aquat Toxicol       Date:  2010-07-23       Impact factor: 4.964

Review 6.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 7.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

Review 8.  Novel therapeutic targets for pancreatic cancer.

Authors:  Shing-Chun Tang; Yang-Chao Chen
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 9.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 10.  Metalloproteinases as mediators of inflammation and the eyes: molecular genetic underpinnings governing ocular pathophysiology.

Authors:  Mahavir Singh; Suresh C Tyagi
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.